Zymeworks
Zymeworks' revenue rose 38.9% to $106 million in fiscal 2025. Its operating margin was −87.3%, up from −179.7% a year earlier. Free cash flow was −$35 million. It paid out $42 million in dividends and buybacks. The diluted share count fell 0.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Zymeworks does
Zymeworks is a biotechnology company that describes itself as managing a portfolio of licensed healthcare assets while developing its own drug candidates. Its pipeline is built on two technology platforms: multispecific antibody therapeutics, which are antibodies that bind more than one target, and antibody-drug conjugates, which attach a toxic drug to an antibody. It aims at cancer, inflammation and autoimmune disease.
Its strategy is to collect royalties and milestone payments on drugs that partners develop and sell. Its licensed products include Ziihera (zanidatamab-hrii) and pasritamig. It depends on partners, including Jazz, BeOne and Johnson and Johnson, to develop and sell zanidatamab and other candidates. It also seeks new partners to share the cost and risk of late-stage development.
Zymeworks says that as its royalty portfolio matures it may use spare cash to buy back its own shares, and that it will also invest in acquisitions and its own research. It calls this royalty-led strategy unproven.
Its biggest risks, as it describes them
- Its royalty-focused strategy of gathering licensed assets is unproven and may not work.
- It depends on partners such as Jazz, BeOne and Johnson and Johnson to develop and sell zanidatamab and other candidates.
- Deals it makes to buy assets could disrupt the business or dilute shareholders.
- Its candidates may fail in trials or lose priority, so it may not build a pipeline.
- It may struggle to find new partners, which face strong competition for the same deals.
Income statement
Zymeworks lost money in fiscal 2025: a net loss of $81 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 253 | 492 | 374 | 226 | 229 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 4.0x | 5.7x | 7.4x | 3.4x | 5.9x |
| Quick ratio | 4.0x | 5.7x | 7.4x | 3.4x | 5.9x |
Cash flow
Projections
Project Zymeworks' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Zymeworks says to expect
- Full year 2026: revenue and adjusted EBITDA
The Company has increased its 2026 financial guidance for total revenue to be between $337 million and $351 million (previously between $278 million and $292 million) and adjusted EBITDA to be between $176 million and $190 million (previously between $114 million and $128 million), excluding the impact of any future transactions.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Zymeworks shares on the open market, and 4 insiders sold $4.7 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jan 12, 2026 | Kenneth GalbraithChair & CEO, Director | Sold | 30,424 | $22.67 | $689,712 | Form 4 |
| Jan 12, 2026 | Paul Andrew MooreChief Scientific Officer | Sold | 9,560 | $22.67 | $216,725 | Form 4 |
| Jan 12, 2026 | Jeffrey T L SmithEVP & Chief Medical Officer | Sold | 9,310 | $22.67 | $211,058 | Form 4 |
| Jan 12, 2026 | Mark HollywoodEVP & Chief Operating Officer | Sold | 6,120 | $22.67 | $138,740 | Form 4 |
| Jan 5, 2026 | Kenneth GalbraithChair & CEO, Director | Sold | 54,343 | $25.10 | $1.4 million | Form 4 |
| Jan 5, 2026 | Paul Andrew MooreChief Scientific Officer | Sold | 20,110 | $25.10 | $504,761 | Form 4 |
| Jan 5, 2026 | Jeffrey T L SmithEVP & Chief Medical Officer | Sold | 10,538 | $25.10 | $264,504 | Form 4 |
| Dec 22, 2025 | Kenneth GalbraithChair & CEO, Director | Sold | 47,528 | $27.02 | $1.3 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −240.5% | −146.5% | 6.3% |
| Altman Z'' | 2.84 | −1.97 | −3.24 |
| Accruals ratio | −0.1% | −2.4% | −11.9% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Pass |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | — | — | — |
Compare
Put Zymeworks side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Zymeworks | FY25 | 38.9% | −87.3% | −32.6% | — | — | — | |
| Zevra Therapeutics | FY25 | 350.9% | −59.1% | −2.3% | −218.8% | — | 5 | Compare |
| UroGen Pharma | FY25 | 21.4% | −113.7% | −148.2% | — | — | 2 | Compare |
| Nurix Therapeutics | FY25 | 54.0% | −340.2% | −313.7% | — | — | — | Compare |
| Eton Pharmaceuticals | FY25 | 104.9% | −1.1% | 12.8% | −1.9% | 1.4x | 4 | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 39 | 27 | 412 | 76 | 76 | 106 |
| Revenue growth | — | −31.5% | 1,446.0% | −81.6% | 0.4% | 38.9% |
| Gross profit | — | — | — | — | — | — |
| Research and development | 171 | 200 | 209 | 144 | 135 | 137 |
| Operating income | −188 | −216 | 130 | −138 | −137 | −92 |
| Net income | −181 | −212 | 124 | −119 | −123 | −81 |
| Diluted EPS (US$) | −3.58 | −4.61 | 1.90 | −1.72 | −1.62 | −1.08 |
| Diluted shares (millions) | 50 | 52 | 65 | 69 | 76 | 75 |
| Cash flow | ||||||
| Cash from operations | −151 | −192 | 144 | −118 | −110 | −33 |
| Capital expenditure | 4 | 12 | 8 | 2 | 2 | 2 |
| Free cash flow | −156 | −205 | 136 | −121 | −112 | −35 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 30 | 42 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 29 | 11 | 4 | 8 | 18 | 28 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 242 | 253 | 492 | 374 | 226 | 229 |
| Debt incl. finance leases | — | — | — | — | — | — |
| Total assets | — | 389 | 649 | 581 | 463 | 346 |
| Total liabilities | — | 140 | 156 | 116 | 124 | 78 |
| Shareholders' equity | 410 | 249 | 493 | 465 | 339 | 268 |
| Margins and ratios | ||||||
| Gross margin | — | — | — | — | — | — |
| Operating margin | −481.3% | −808.2% | 31.6% | −181.6% | −179.7% | −87.3% |
| Net margin | −463.5% | −794.0% | 30.1% | −156.1% | −160.8% | −76.6% |
| Free cash flow margin | −399.8% | −767.8% | 33.0% | −158.9% | −146.8% | −32.6% |
| Rule of 40 (growth + FCF margin) | — | −799.3% | 1,479.0% | −240.5% | −146.5% | 6.3% |
| Return on capital | — | — | — | — | — | — |
| Return on equity | — | — | 33.5% | −24.8% | −30.5% | −26.7% |
| Return on assets | — | — | 24.0% | −19.3% | −23.5% | −20.0% |
| Net debt to EBITDA | — | — | — | — | — | — |